ClinicalTrials.gg
RecruitingNCT05885503Updated Sep 5, 2023

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

A Phase 3 interventional study of RC-28E and Aflibercept in Diabetic Macular Edema, sponsored by RemeGen Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.

Planned enrollment
15th of 65
316 · median 140
Started
2023
with 10 others
Phase 3
25 of 72
4 open now
Primary completion
2026-06
later than 10 of 21 live
Registered
49th of 72
by date
Lead sponsor
3 of 72
RemeGen Co., Ltd.

Among the 72 studies in Macular Edema with a site in China, this one is the 15th largest by planned enrollment of the 65 interventional ones that give a count, is one of 11 that started in 2023, is one of 25 in phase 3, reaches primary completion later than 10 of the 21 other live ones, and was the 49th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Macular Edema with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosed with type I or type II diabetes mellitus.
  • (HBA1c) of less than or equal to (≤) 10% within 2 months prior to Day 1.
  • Ability and willingness to undertake all scheduled visits and assessments.
  • The study eye must meet the following requirements:

    • macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea.
    • decreased visual acuity attributable primarily to DME, the best corrected visual acuity (BCVA) 19 or more letters, 78 letters or less.

Exclusion criteria

Exclusion Criteria:

  • The study eye with high risk of proliferative diabetic retinopathy.
  • The macular edema of the study eye is mainly caused by other diseases or factors other than DME.
  • Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye.
  • Administration of IVT any other anti-VEGF drugs in the study eye within 3 months and/or in the other eye within 7 days prior to Day 1.
  • Any intraocular long-acting or sustained release treatment (e.g., dexamethasone intravitreal implant) in the study eye within 6 months prior to Day 1.
  • Active intraocular or periocular infection or active intraocular inflammation in either eye.
  • The study eye with poorly controlled glaucoma.
  • A history of idiopathic or related uveitis in either eye.
  • History of stroke (cerebrovascular accident) or myocardial infarction within 6 months prior to Day 1.
  • Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest.
  • Currently pregnant or breastfeeding, or intend to become pregnant during the study.
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye.
  • Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye.
  • Other protocol-specified inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    RC-28E

    RC-28E 2.0 mg will be initially intravitreal injected (IVT) 5 times at 4 week intervals from week 0 to week 16, then every 8 weeks until week 48.

    Biological: RC-28E

  • Active comparator
    Aflibercept

    Aflibercept 2.0mg will be received IVT once every 4 weeks for 5 consecutive times from week 0 to week 16, then once every 8 weeks till week 48.

    Biological: Aflibercept

Interventions

  • BiologicalRC-28E

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

  • BiologicalAflibercept

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

06

What researchers measure

Primary outcomes

  1. Change from baseline in BCVA at Week 52

    BCVA=best-corrected visual acuity; Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts at a starting distance of 4 meters

    Time frame: Baseline, week 52

Secondary outcomes

  1. Average change in BCVA from baseline over the period week 40 through week 52

    For each subject, this endpoint is defined as the average of the changes from baseline to weeks 40, 44, 48 and 52

    Time frame: Baseline, weeks 40, 44, 48 and 52

  2. Change from baseline in BCVA over time

    BCVA will be assessed at each visit

    Time frame: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  3. Proportion of patients gaining >15, >10, >5, or >0 letters in BCVA from baseline at Week 52

    Proportion of patients of gaining 4 types of letter counting in BCVA, respectively

    Time frame: Baseline, week 52

  4. Proportion of patients avoiding a loss of >15, >10, >5, or >0 letters in BCVA from baseline at Week 52

    Proportion of patients of reducing 4 types of letter counting in BCVA, respectively

    Time frame: Baseline, week 52

  5. Change from baseline in CST at Week 52

    CST=central subfield thickness

    Time frame: Baseline, week 52

  6. Mean change from baseline in CST over a period of week 40 through week 52

    CST=central subfield thickness

    Time frame: Baseline, weeks 40, 44, 48 and 52.

  7. Change from baseline in CST over time

    The change of CST will be assessed from baseline to 52 weeks by every 4 week intervals

    Time frame: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  8. Proportion of patients with absence of intraretinal fluid at Week 52

    Proportion of patients whose intraretinal fluid are completely improved

    Time frame: Baseline, week 52

  9. Proportion of patients with absence of subretinal fluid at Week 52

    Proportion of patients whose subretinal fluid are completely improved

    Time frame: Baseline, week 52

  10. Proportion of patients with absence of intraretinal fluid and subretinal fluid at Week 52

    Proportion of patients whose intraretinal fluid and subretinal fluid are both completely improved

    Time frame: Baseline, week 52

  11. Proportion of patients with a >2-step or>3-step DRS worsening from baseline on ETDRS DRSS at Week 52

    DRSS=Diabetic Retinopathy Severity Scale

    Time frame: Baseline, week 52

  12. Proportion of patients who develop new PDR or high risk PDR at Week 52

    PDR=proliferative diabetic retinopathy

    Time frame: Baseline, week 52

  13. Incidence and severity of ocular adverse events and non-ocular adverse events

    during the study

    Time frame: 0~52 weeks

  14. Plasma concentration of RC28-E over time

    during the study

    Time frame: Baseline, weeks 16, 36 and 48

  15. Presence of ADAs during the study relative to the presence of ADAs at baseline

    during the study

    Time frame: Baseline, weeks 12, 24, 36 and 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 36 months is above that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
Jun 2, 2023
StartActual
Jun 8, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Sep 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05885503
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Jun 8, 2023
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Sep 5, 2023

Study contacts

Binghua Xiao
Contact
xiaosir522@163.com
86-010-58076833
Youxin Chen
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RC28-E protein

Start the discussion